stockrowRecursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
Follow RXRX
Alert me
Recursion Pharmaceuticals, Inc. (RXRX) Operating margin
Recursion Pharmaceuticals, Inc.'s operating margin over the twelve months to 30 September 2026 was −725.4%, up 142.4 percentage points from fiscal 2025 (−867.9%). Over the past ten years it has ranged from −5,385.2% (fiscal 2019) to −616.7% (fiscal 2022); the current reading is higher than 73% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | −867.9% | (53.78) |
| FY2024 | −814.1% | (28.76) |
| FY2023 | −785.3% | (168.59) |
| FY2022 | −616.7% | 616.74 |
| FY2022 | −1,233.5% | 562.31 |
| FY2021 | −1,795.8% | 1,795.78 |
| FY2021 | −3,591.6% | (1,455.91) |
| FY2020 | −2,135.7% | 2,135.67 |
| FY2020 | −4,271.3% | (1,578.75) |
| FY2019 | −2,692.6% | 2,692.59 |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Sep 2026 | −664.0% | 1,095.74 |
| Jun 2026 | −1,759.7% | 225.86 |
| Mar 2026 | −1,985.6% | (1,680.71) |
| Dec 2025 | −304.8% | 3,022.73 |
| 23 more quarters | Free account |
Against its own ten years
Operating margin against peers
| Company | Operating margin |
|---|---|
| ADMA ADMA Biologics Inc compare | 46.5% |
| VCEL Vericel Corporation compare | 8.32% |
| MBX MBX Biosciences, Inc. compare | 0.00% |
| BHVN Biohaven Ltd. compare | 0.00% |
| PHVS Pharvaris N.V. compare | 0.00% |
| PVLA Palvella Therapeutics, Inc. compare | 0.00% |
| RXRX Recursion Pharmaceuticals, Inc. | −725.4% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −900.1% |
| CLDX Celldex Therapeutics, Inc. compare | −36,733.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on RXRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement